NASDAQ:TMCI Treace Medical Concepts (TMCI) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free TMCI Stock Alerts $4.38 -0.05 (-1.13%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.33▼$4.7750-Day Range$4.17▼$13.7452-Week Range$3.92▼$27.70Volume3.91 million shsAverage Volume1.36 million shsMarket Capitalization$271.60 millionP/E RatioN/ADividend YieldN/APrice Target$13.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Treace Medical Concepts alerts: Email Address Treace Medical Concepts MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside209.8% Upside$13.57 Price TargetShort InterestBearish6.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.31Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.88) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.70 out of 5 starsMedical Sector444th out of 925 stocksSurgical & Medical Instruments Industry57th out of 100 stocks 4.1 Analyst's Opinion Consensus RatingTreace Medical Concepts has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageTreace Medical Concepts has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Treace Medical Concepts' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.73% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 10.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMCI. Previous Next 2.1 News and Social Media Coverage News SentimentTreace Medical Concepts has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.Search Interest5 people have searched for TMCI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.Percentage Held by Insiders24.43% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Treace Medical Concepts' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.88) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Treace Medical Concepts' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Treace Medical Concepts Stock (NASDAQ:TMCI)Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.Read More TMCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMCI Stock News HeadlinesMay 11, 2024 | americanbankingnews.comAnalysts Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $19.58May 10, 2024 | finance.yahoo.comEarnings Update: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Just Reported And Analysts Are Trimming Their ForecastsMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 10, 2024 | americanbankingnews.comTreace Medical Concepts (NASDAQ:TMCI) PT Lowered to $16.00May 10, 2024 | americanbankingnews.comTreace Medical Concepts (NASDAQ:TMCI) Stock Rating Lowered by Morgan StanleyMay 9, 2024 | msn.comMorgan Stanley Downgrades Treace Medical Concepts (TMCI)May 9, 2024 | msn.comBTIG Downgrades Treace Medical Concepts (TMCI)May 8, 2024 | msn.comOrthopedic Devices Maker Treace Medical Concepts' Gloomy Forecast Cast Concerns Over Long-Term ViabilityMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 8, 2024 | msn.comTreace Medical crashes as guidance cut prompts J.P. Morgan downgradeMay 8, 2024 | investorplace.comWhy Is Treace Medical Concepts (TMCI) Stock Down 59% Today?May 8, 2024 | finance.yahoo.comTreace Medical Concepts Inc (TMCI) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | finance.yahoo.comTreace Medical Concepts Inc (TMCI) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss WidensMay 7, 2024 | finance.yahoo.comTreace Medical Concepts Reports First Quarter 2024 Financial ResultsApril 27, 2024 | nasdaq.comTreace Medical Concepts is Now Oversold (TMCI)April 24, 2024 | globenewswire.comTreace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA TourApril 17, 2024 | finance.yahoo.comTreace to Present at Bank of America Health Care ConferenceApril 16, 2024 | globenewswire.comTreace Announces First Annual National Bunion DayApril 15, 2024 | investorplace.com7 Stable Stocks for 50% Returns by Early 2025April 9, 2024 | globenewswire.comTreace to Report First Quarter 2024 Financial ResultsMarch 25, 2024 | globenewswire.comTreace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient MilestoneMarch 1, 2024 | seekingalpha.comTreace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Just Reported And Analysts Have Been Lifting Their Price TargetsMarch 1, 2024 | morningstar.comTreace Medical Concepts IncFebruary 29, 2024 | finance.yahoo.comTreace Medical Concepts Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comBuy Rating on Treace Medical Concepts: Promising Financial Outlook and Strategic Product Innovation Drive GrowthSee More Headlines Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TMCI CUSIPN/A CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees516Year FoundedN/APrice Target and Rating Average Stock Price Target$13.57 High Stock Price Target$27.50 Low Stock Price Target$5.50 Potential Upside/Downside+209.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,530,000.00 Net Margins-27.93% Pretax Margin-27.93% Return on Equity-39.66% Return on Assets-22.24% Debt Debt-to-Equity Ratio0.42 Current Ratio3.98 Quick Ratio3.76 Sales & Book Value Annual Sales$187.12 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book2.15Miscellaneous Outstanding Shares62,010,000Free Float46,859,000Market Cap$271.60 million OptionableOptionable Beta0.37 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. John T. Treace (Age 52)CEO, Founder & Director Comp: $1.09MMr. Mark L. Hair CPA (Age 54)Chief Financial Officer Comp: $599.7kMr. Aaron J. Berutti (Age 45)Senior Vice President of Sales Comp: $484.22kMr. Terry W. Lubben (Age 59)Senior Vice President of Operations Ms. Julie D. Dewey (Age 63)Chief Communications & Investor Relations Officer Mr. Scot M. Elder J.D. (Age 49)Chief Legal & Compliance Officer and Corporate Secretary Mr. Nathan MinnichSenior Vice President of MarketingMr. Daniel E. Owens (Age 52)Chief Human Resources Officer Dr. Sean F. Scanlan Ph.D. (Age 42)Chief Innovation Officer Ms. Shana ZinkSenior Vice President of Clinical Affairs, Medical Education & ReimbursementMore ExecutivesKey CompetitorsSI-BONENASDAQ:SIBNAtrionNASDAQ:ATRIEmbectaNASDAQ:EMBCSilk Road MedicalNASDAQ:SILKIradimedNASDAQ:IRMDView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 9,610 shares on 5/10/2024Ownership: 6.968%William Blair Investment Management LLCSold 538,523 shares on 5/8/2024Ownership: 3.772%TimesSquare Capital Management LLCSold 364,991 shares on 5/7/2024Ownership: 2.241%GSA Capital Partners LLPSold 9,318 shares on 5/3/2024Ownership: 0.112%RiverPark Advisors LLCBought 7,952 shares on 5/3/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions TMCI Stock Analysis - Frequently Asked Questions Should I buy or sell Treace Medical Concepts stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TMCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMCI, but not buy additional shares or sell existing shares. View TMCI analyst ratings or view top-rated stocks. What is Treace Medical Concepts' stock price target for 2024? 7 brokers have issued 1 year price objectives for Treace Medical Concepts' shares. Their TMCI share price targets range from $5.50 to $27.50. On average, they predict the company's share price to reach $13.57 in the next twelve months. This suggests a possible upside of 209.8% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts. How have TMCI shares performed in 2024? Treace Medical Concepts' stock was trading at $12.75 at the beginning of the year. Since then, TMCI shares have decreased by 65.6% and is now trading at $4.38. View the best growth stocks for 2024 here. When is Treace Medical Concepts' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our TMCI earnings forecast. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.30) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.30). The firm earned $51.11 million during the quarter, compared to analysts' expectations of $49.07 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 39.66% and a negative net margin of 27.93%. The business's revenue for the quarter was up 21.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.23) earnings per share. What ETF holds Treace Medical Concepts' stock? iShares U.S. Medical Devices ETF holds 289,221 shares of TMCI stock, representing 0.06% of its portfolio. What guidance has Treace Medical Concepts issued on next quarter's earnings? Treace Medical Concepts updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $201.0 million-$211.0 million, compared to the consensus revenue estimate of $222.8 million. When did Treace Medical Concepts IPO? Treace Medical Concepts (TMCI) raised $150 million in an initial public offering on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. Who are Treace Medical Concepts' major shareholders? Treace Medical Concepts' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.97%), William Blair Investment Management LLC (3.77%), TimesSquare Capital Management LLC (2.24%), Wealth Enhancement Advisory Services LLC (0.39%), Oak Ridge Investments LLC (0.20%) and GSA Capital Partners LLP (0.11%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMCI) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
